✦ LIBER ✦

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

✍ Scribed by Paul William Manley; Sandra W. Cowan-Jacob; Jürgen Mestan

Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 373 KB
Volume: 1754
Category: Article
ISSN: 1570-9639
DOI: 10.1016/j.bbapap.2005.07.040

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dynamic change of T315I BCR-ABL kinase d

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors

✍ Wan-Seok Kim; Dongho Kim; Dong-Wook Kim; Il-Young Kweon; Soo-Hyun Kim; Hyun-Gyun 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB 👁 1 views

## Abstract We analysed the dynamic change of imatinib‐resistant mutations in BCR‐ABL kinase domain focusing on T315I mutation during dasatinib or nilotinib therapy. Fifty‐five imatinib‐resistant chronic myeloid leukaemia patients (32 patients with imatinib‐resistant mutations and 23 patients witho

Advances in the structural biology, desi

Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis

✍ Paul William Manley; Guido Bold; Josef Brüggen; Gabrielle Fendrich; Pascal Furet 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 503 KB

Complexity of BCR-ABL kinase domain muta

Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia

✍ Dushyant Verma; Carmen Fava; Hagop Kantarjian; Jorge Cortes 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Practical advice for determining the rol

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

✍ Elias Jabbour; Susan Branford; Giuseppe Saglio; Dan Jones; Jorge E. Cortes; Hago 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 288 KB 👁 1 views

## Abstract Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are rapidly changing the treatment landscape for CML. In this review, the authors discuss currently available thera